We present here a mutation assay with little bias which incorporates high-throughput DNA sequencing technology. Our strategy is simple: 1) expose cells to a test compound, 2) isolate colonies, and 3) carry out whole-genome sequencing of the clones. In this pilot study, we used Salmonella typhimurium TA100 as a tester strain and successfully detected mutations induced by the mutagen 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide (AF-2). We believe that this new mutation assay will be a very useful tool in hazard assessment of chemicals.
Introduction
In conducting a hazard assessment for a newly developed chemical compound, mutation assays are regarded as among the most important toxicity tests. This is because mutation assays are often used as surrogate tests for carcinogenicity, and manufacturers tend to decide whether to quit or continue development based on the results of mutation assays. Thus, it is very important to develop a reliable mutation assay that is free from false positive and false negative results.
In most of the currently used mutation assays, mutations in a speciˆc gene (target gene) are detected by monitoring a phenotypic change in the cells. As an example, the Ames test, which was developed in 1970's, is the most widely used mutation assay. The tester strain Salmonella typhimurium TA100 has a point mutation in its hisG gene at codon 69 and cannot grow and form colonies on a minimal agar plate lacking histidine. However, if a reverse mutation occurs in the same codon of the gene, the revertant is now able to form colonies on minimal medium. Thus, mutagenicity is evaluated by counting the revertant colonies induced by a test compound. Although this is a very simple and inexpensive test system it has many biases, mostly related to the base sequence and the types of mutations that can arise at the target site. For example, codon 69 of the hisG gene of TA100 is CCC, so that this tester strain preferentially detects mutations at G:C base pairs, not A:T base pairs, and because of this sequence bias, it is recommended to use several other strains in addition to TA100 which can detect diŠerent mutation spectrum such as TA98, TA102, and TA1537.
This inconvenience motivated us to develop a new forward mutation assay that does not rely on any phenotypic selection. Our strategy is simple: 1) expose cells to the test compound, 2) isolate colonies, and 3) carry out whole-genome sequencing of the clones. This strategy became possible only after recent technical advancements in performance of next-generation DNA sequencers and reductions in running costs. Although any cell type, including human cell lines, may be used in this system, we began with Salmonella typhimurium TA100 so that we could compare our new strategy and the conventional Ames test. Another reason for choosing a bacterial strain is its small genome size and monoploidy that facilitates this strategy.
Materials and Methods
The Ames test was carried out with TA100 as the tester strain and 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide (AF-2; 0.01 mg/plate) as the test chemical. AF-2 was purchased by Wako (Osaka, Japan). S9 mix was not applied in this test. Experimental details are provided at``supporting information'' (http://www.j-ems. org/journal/supporting.html).
Ten revertant colonies were randomly isolated,ˆve from the solvent control group andˆve from the AF-2exposed group, and subjected to DNA puriˆcation. Whole-genome sequencing of each of the 10 clones was carried out in a single run by using a high-throughput DNA sequencer, MiSeq (Illumina, San Diego, CA). The sequencing data compiled to fastaqˆles were analyzed using CLC Genomics Workbench ver.5 software (CLC 
Results and Discussions
AF-2 showed mutagenicity in TA100 strain as expected. The mean number of revertant colonies obtained for the solvent control (DMSO) was 141±14/plate (n＝3), and for the AF-2-exposed group it was 530±40/plate (n＝3).
Whole-genome sequencing of randomly selected 10 clones was carried out. For all 10 clones, the sequence data were mapped over the whole genome, and the average coverage of each clone ranged from 18.4× to 42.7×, and the average of the ten clones was 31.5× as shown in Table S1 (Supporting information, http:// www.j-ems.org/journal/supporting.html). The diŠerences in genomic sequences between the reference strain Salmonella typhimurium LT2 and TA100 are shown in Tables S2 and S3 (Supporting information). In addition to these diŠerences, a large deletion (49,906 bp) including DNA excision repair gene, uvrB was observed in TA100 which is consistent with the previous report (1). The genes encoded in this deleted region are shown in Fig. S1 (Supporting information) .
The mutations detected in the AF-2 and solvent (DMSO) groups are listed in Tables 1 and 2 , and the mapping data is shown in Fig. S2 (Supporting information). Table 1 lists the mutations in codon 69 of the hisG gene, in which the TA100 sequence is CCC (Pro). Mutations were detected in all the clones tested, meaning that phenotypic reversion was conˆrmed by alterations of the genetic sequence. However, there was only one true revertant clone with the wild-type sequence CTC (Leu); the other 9 clones had codon-69 sequences that specify other amino acids. The observed base substitutions were CªA, CªT, CªG at base position 205 and CªA, CªT at base position 206. These base substitutions have been reported in hisG gene of some revertant colonies (2) . Table 2 lists the mutations observed at other genomic sites. Only one clone in the DMSO-treated group had an additional mutation, whereasˆve unique mutations were observed in three clones of the AF-2-treated group.
Of these six mutations (AF-2＋control), four were silent mutations and so did not produce any amino acid changes. We also looked for small insertions/deletions and large insertions/deletions, but could notˆnd any such changes induced by AF-2.
The mutational frequencies/genome were calculated as 0.2 in the DMSO-treated group, and 1.0 in the AF-2treated group. These can be further expressed as 4.2 mutations/10 8 bp in the DMSO group and 21 mutations/10 8 bp in the AF-2 group. In this calculation, mutations in hisG gene codon 69 were not included.
As for the mutation spectrum, the data in Table 1 should also be omitted because the mutational target is limited to hisG codon 69, and this will cause strong bias. Looking at Table 2 , there is only one mutation in the DMSO-treated group, at an A:T base pair. On the other hand, in the AF-2-treated group, allˆve mutations occurred at G:C base pairs and there were two G:CªA:T (40z), one G:CªT:A (20z) and two G:CªC:G (40z) mutations, which is somewhat consistent with a previous report about the mutation spectrum induced by AF-2 in the lacI gene of Escherichia coli (3) [G:CªA:T (33.8z), G:CªT:A (52.4z), G:CªC:G (6.9z), A:TªT:A (6.2z), A:TªG:C (0.7z)]. Also listed in Table 2 are the sequences surrounding the mutation sites. AF-2-induced mutations with some sequence preference (Fig. S3) ; however, more data will be required to determine the preference with precision.
As this new assay uses high-throughput DNA sequencing to detect mutations without phenotypic selection, it is thought to be a bias-free method. What further issues need to be considered so as to enhance the practicality of this new mutation assay? In this pilot study, we selected revertant colonies to conˆrm detectability of mutations by monitoring hisG codon-69 mutations, and we successfully detected those mutations in all 10 clones tested. Thus, having proved the principle of the method, we suggest that from now on it is better to produce colonies on a rich medium such as LB and randomly pick colonies for completely non-biased mutation detection.
Another issue is how to establish the criteria to deˆne positive and negative results. To develop the criteria it is necessary to have an accurate estimate of the spontaneous mutation frequency. The only way to obtain this is to increase the denominator, i.e., combine all future data on spontaneous mutations. Assuming we are able to determine the`real' spontaneous mutation frequency, we could then calculate the probability that all of the observed mutations are spontaneous mutations. Spontaneous mutation is rare event and occurs randomly, so that it follows the Poisson distribution [1] shown below:
Here, l is the number of expected spontaneous mutations, and k is the number of observed mutations. The probability that all of the observed mutations are spontaneous mutations can be calculated by using equation [2] :
Assuming that the spontaneous mutation frequency observed in this pilot study is close to the true rate, it is one mutation perˆve clones (i.e., l＝1). On the other hand, ve mutations were found in the AF-2-treated group per ve clones (i.e., k＝5; the hisG mutations were not included in this calculation). In this situation, the probability that allˆve mutations were of spontaneous origin is calculated as P(XAE5)＝0.0037, meaning it is very likely that the mutations were actually induced by AF-2. An Excel sheet for calculating the probability is shown in Table S4 (Supporting information). If you input the l value, P(XAEk) values are automatically calculated. By using the P(XAEk) value, we can decide positive or negative results, according to the proper threshold such as PÃ0.05 or 0.01.
In summary, high-throughput next-generation DNA sequencing technology can be the basis of a practical mutation assay which delivers bias-free mutation spectra and frequencies. The same strategy as outlined here can be applied to other organisms such as yeasts or human cell lines. We predict that this strategy will become a gold standard for genotoxicity tests in the not-toodistant future.
